These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and classification of myelodysplastic syndromes. Hasserjian RP; Germing U; Malcovati L Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372 [TBL] [Abstract][Full Text] [Related]
36. Management of patients with lower-risk myelodysplastic syndromes. Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487 [TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Sallman DA; Tanaka TN; List A; Bejar R Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689 [TBL] [Abstract][Full Text] [Related]
38. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations. DiGennaro J; Sallman DA Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186 [TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndromes: what do hospitalists need to know? Zeidan AM; Faltas B; Douglas Smith B; Gore S J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Liu W; Zhou Z; Chen L; Wang X Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]